211 related articles for article (PubMed ID: 22261672)
21. Molecular targets in the discovery and development of novel antimetastatic agents: current progress and future prospects.
Wong MS; Sidik SM; Mahmud R; Stanslas J
Clin Exp Pharmacol Physiol; 2013 May; 40(5):307-19. PubMed ID: 23534409
[TBL] [Abstract][Full Text] [Related]
22. Advances in targeted therapy for melanoma.
Friedlander P; Hodi FS
Clin Adv Hematol Oncol; 2010 Sep; 8(9):619-27. PubMed ID: 21157411
[TBL] [Abstract][Full Text] [Related]
23. [Melanoma and search for therapeutic targets].
de la Fouchardière A
Ann Pathol; 2011 Nov; 31(5 Suppl):S123-4. PubMed ID: 22054449
[No Abstract] [Full Text] [Related]
24. Targeted cancer therapy: promise and reality.
Klein S; Levitzki A
Adv Cancer Res; 2007; 97():295-319. PubMed ID: 17419951
[TBL] [Abstract][Full Text] [Related]
25. Molecularly targeted therapy for melanoma: current reality and future options.
Becker JC; Kirkwood JM; Agarwala SS; Dummer R; Schrama D; Hauschild A
Cancer; 2006 Nov; 107(10):2317-27. PubMed ID: 17039502
[TBL] [Abstract][Full Text] [Related]
26. Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature.
Satzger I; Küttler U; Völker B; Schenck F; Kapp A; Gutzmer R
Dermatology; 2010; 220(1):77-81. PubMed ID: 19996579
[TBL] [Abstract][Full Text] [Related]
27. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
28. Histone deacetylases (HDACs) as mediators of resistance to apoptosis in melanoma and as targets for combination therapy with selective BRAF inhibitors.
Lai F; Jin L; Gallagher S; Mijatov B; Zhang XD; Hersey P
Adv Pharmacol; 2012; 65():27-43. PubMed ID: 22959022
[TBL] [Abstract][Full Text] [Related]
29. Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy?
Passeron T; Lacour JP; Allegra M; Ségalen C; Deville A; Thyss A; Giacchero D; Ortonne JP; Bertolotto C; Ballotti R; Bahadoran P
Exp Dermatol; 2011 Dec; 20(12):1030-2. PubMed ID: 22092579
[TBL] [Abstract][Full Text] [Related]
30. A review of novel therapies for melanoma.
Karimkhani C; Gonzalez R; Dellavalle RP
Am J Clin Dermatol; 2014 Aug; 15(4):323-37. PubMed ID: 24928310
[TBL] [Abstract][Full Text] [Related]
31. Systemic therapy for metastatic malignant melanoma--from deeply disappointing to bright future?
Lorigan P; Eisen T; Hauschild A
Exp Dermatol; 2008 May; 17(5):383-94. PubMed ID: 18312390
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy and targeted agents for thymic malignancies.
Girard N
Expert Rev Anticancer Ther; 2012 May; 12(5):685-95. PubMed ID: 22594902
[TBL] [Abstract][Full Text] [Related]
33. Driving in the melanoma landscape.
Herlyn M
Exp Dermatol; 2009 Jun; 18(6):506-8. PubMed ID: 19366372
[TBL] [Abstract][Full Text] [Related]
34. Targeting oncogenic drivers and the immune system in melanoma.
McArthur GA; Ribas A
J Clin Oncol; 2013 Feb; 31(4):499-506. PubMed ID: 23248252
[TBL] [Abstract][Full Text] [Related]
35. Molecular targeted therapy for patients with melanoma: the promise of MAPK pathway inhibition and beyond.
Sullivan RJ; Atkins MB
Expert Opin Investig Drugs; 2010 Oct; 19(10):1205-16. PubMed ID: 20687784
[TBL] [Abstract][Full Text] [Related]
36. The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications.
Haluska F; Pemberton T; Ibrahim N; Kalinsky K
Semin Oncol; 2007 Dec; 34(6):546-54. PubMed ID: 18083378
[TBL] [Abstract][Full Text] [Related]
37. New therapeutical strategies in the treatment of metastatic disease.
Julia F; Thomas L; Dalle S
Dermatol Ther; 2012; 25(5):452-7. PubMed ID: 23046024
[TBL] [Abstract][Full Text] [Related]
38. Imatinib targeting of KIT-mutant oncoprotein in melanoma.
Jiang X; Zhou J; Yuen NK; Corless CL; Heinrich MC; Fletcher JA; Demetri GD; Widlund HR; Fisher DE; Hodi FS
Clin Cancer Res; 2008 Dec; 14(23):7726-32. PubMed ID: 19047099
[TBL] [Abstract][Full Text] [Related]
39. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
Willmore-Payne C; Holden JA; Tripp S; Layfield LJ
Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115
[TBL] [Abstract][Full Text] [Related]
40. Targeted treatment for melanoma.
Monga M; Abraham J
Expert Rev Anticancer Ther; 2012 Sep; 12(9):1113-5. PubMed ID: 23098110
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
